Transforming brain health through earlier detection — delivered where care happens.

We build the diagnostic infrastructure that brings cognitive disease detection earlier, closer to patients, and into the hands of clinicians who can act on it.​

 — OUR MISSION — 

 

 To change the trajectory of brain disease by making early, accurate diagnosis routine, actionable, and accessible — through connected telehealth care, retinal imaging, and blood-based biomarkers that work together across the full patient journey. 

 — THE PROBLEM WE'RE SOLVING — 

 

Brain disease advances years before a patient ever walks into a clinic. 

 75%

 Of dementia cases are undiagnosed or diagnosed only after significant irreversible decline has already occurred — a window where early intervention could change everything. 

Years-long diagnostic delays push patients past the window for therapeutic benefit from emerging treatments targeting amyloid pathology.
PCPs lack specialist bandwidth — neurology wait times of 6–12+ months are common, and most primary care offices have no clear cognitive referral pathway.
Biomarker access is fragmented — pTau-217, NfL, and retinal imaging exist, but no integrated platform makes them actionable at the point of primary care.

 — INTEGRATED PLATFORMS — 

 

One continuum from first concern to clinical action. 

Each platform closes a key gap in the cognitive care journey:
access, detection, and scalable diagnostics. 

TELEHEALTH CARE
BrainHealth Clinic Logo_Vertical_Color_331

BrainHealth Clinic™

BrainHealth Clinic is a comprehensive cognitive care telehealth platform that manages the full patient journey — from first concern through ongoing treatment and support. We handle assessment, imaging and biomarker testing, neurology access, patient and caregiver engagement, and longitudinal management so patients receive specialized cognitive care without gaps or delays.
  • Fast referral outreach and scheduling
  • Full cognitive assessment, imaging, and biomarker testing
  • Neurology consultation in weeks, not months
RETINAL IMAGING
retina (002)

Afina™ Retinal Imaging*

A cloud-based AI imaging pathway designed to identify retinal signatures associated with neurodegenerative disease and treatment safety monitoring.

  • Non-invasive scan performed in minutes
  • AI-enabled analysis for disease signatures
  • Research and validation with leading partners

 

BLOOD BIOMARKERS
biomarker-1

Duritect™ 

Duritect™ , developed by Durin Life Sciences, and recently acquired by NeuroVision, is a diagnostics platform designed to support earlier detection and longitudinal monitoring of neurodegenerative diseases.
  • Programs in development include: Alzheimer’s, Parkinson’s disease, and ALS
  • Designed for real-world clinical deployment*
  • Part of NeuroVision’s integrated BrainHealth Platform

 *Certain components of the platform are under development or investigational and are not currently FDA-cleared or approved. 

 — THE SCIENCE — 

 

Diagnostics plus care delivery — not diagnostics in isolation. 

NeuroVision's advantage is the ability to connect emerging diagnostic tools with clinical workflows that can actually reach patients: primary care identification, teleneurology access, biomarker interpretation, and longitudinal engagement. 

ACCESS
Designed for primary care and health-system workflows.
ACTION
Testing connected to consults, care plans, and next steps
SCALE
Telehealth infrastructure for broad deployment.
DATA
Multi-modal insights across cognition, biomarkers, imaging, and longitudinal care.

 — INVESTORS — 

 

Capital aligned with a mission that matters 

We are venture backed by financial and strategic investors who share our vision to transform neuroscience and access pathways for patients. 

— OUR TEAM —

Leadership and scientific advisors

Our board, team and scientific advisors combine deep medical experience with scientific and business expertise, guided by leaders in neurology, biomarkers and dementia research.

Board of Directors

  • René Chaze

    René Chaze

    Director

    Learn more about René Chaze

    René Chaze is a strategy, operations, and finance executive with 35+ years of leadership experience spanning family office investing, private equity portfolio companies, financial services, and consulting. As a Partner at Tiny Orange Capital, he focuses primarily on high-growth technology sectors including blockchain, digital assets, and life sciences. René previously held senior leadership roles at Edelman Financial Services, including CFO, COO, and Head of M&A. Earlier in his career, he was a Partner at Ernst & Young, where he advised telecom, media and technology clients on tax strategy, structuring, and policy.

  • Ric Edelman

    Ric Edelman

    Director

    Learn more about Ric Edelman

    Ric Edelman founded the nation's largest financial planning firm, which manages $350 billion for 1.4 million families across the United States. He was ranked three times as the nation's #1 Independent Financial Advisor by Barron's, is in two industry Halls of Fame and recipient of three Lifetime Achievement Awards. He holds two patents for financial product innovation, appeared on The Oprah Winfrey Show five times and was once the answer to 21 Across in a New York Times crossword puzzle.

    Edelman is the #1 bestselling author of 14 books on personal finance, with more than 1.2 million copies in eight languages worldwide. At Rowan University, he is Founding Head of the School of Financial Planning; benefactor of Edelman Fossil Park, the Edelman Planetarium and the Edelman Scholars; and the Ric Edelman College of Communications, Humanities and Social Sciences is named in his honor.

  • Len Potter

    Len Potter

    Director

    Learn more about Len Potter

    Leonard A. Potter founded Wildcat Capital Management in 2011 and has served since then as its president and chief investment officer. Mr. Potter also serves as Chairman of Infinity Q Capital Management and as a Senior Managing Director of Vida Ventures, each a fund investment manager. From 2002 through 2009, Mr. Potter was managing director—private equity at Soros Fund Management LLC (“SFM”) where, from May 2005 through July 2009, he served as co-head of its private equity group and as a member of the private equity investment committee. Mr. Potter has served and continues to serve as a director on a number of boards of public and private companies, including Hilton Grand Vacations (NYSE: HGV), Solar Capital Ltd. (NASDAQ: SLRC), Solar Senior Capital Ltd. (NASDAQ: SUNS) and SuRo Capital Corporation (NASDAQ: SSSS).

  • Mark Selna

    Mark Selna, MD

    Director

    Learn more about Mark Selna, MD

    With over 30 years' experience in health system and health plan leadership, as well as in medical practice, Dr. Selna most recently served as President and CEO of Quartz. He is also co-founder of an AI company using data and algorithms to help health systems improve financial, operational, and clinical outcomes.

  • Roy Twyman, MD

    Roy Twyman, MD

    Director

    Learn more about Roy Twyman, MD

    Roy Ervin Twyman, MD, has nearly 20 years' experience in neuroscience pharmaceutical drug development, most recently as senior vice president at Janssen Pharmaceutical Research & Development LLC, where he was the Alzheimer's disease area leader in the Neuroscience Therapeutic Area. Dr. Twyman has served on advisory committees and panels of the U.S. Food and Drug Administration and the Institute of Medicine. Board-certified in psychiatry and neurology, Dr. Twyman was an academic neurologist and has written chapters in several books and published numerous articles in peer-reviewed medical and scientific journals.

  • Steven Verdooner

    Steven Verdooner

    CEO, Director & Co-founder

    Learn more about Steven Verdooner

    Steve is a seasoned, results-driven executive with over 30 years of experience in the ophthalmology, neurology and medical device markets, with a proven track record of launching and leading successful startup businesses. He has expertise in a diverse range of business management including sales and marketing, research and development, operations and regulatory management, brand management, business development and strategic planning. Steve has a proven ability to lead and interface with key opinion leaders, advisory boards, customers, scientists, engineers, Company Boards and the financial community.

    Steve serves as the CEO of NeuroVision Imaging, a company developing retinal and fluid biomarkers for neurodegenerative disease. Steve was co-founder and CEO of Ophthalmic Imaging Systems (1984-2007). OIS was a company dedicated to research, development, marketing, selling and manufacturing diagnostic medical imaging systems and informatics software for the eye care market. Steve led the initial research, market analysis, product development, commercialization strategy, and product launch for a revolutionary new imaging system that was the first of its kind in ophthalmology. Steve was involved in establishing and building the company infrastructure that took OIS to a public offering in 1992 and eventually being sold to Merge Healthcare in 2011. Steve next joined OPKO Health, Inc. as Executive Vice President. OPKO is a publicly traded specialty healthcare company (that engages in the discovery, development, and commercialization of pharmaceutical products, medical devices, vaccines, and diagnostic technologies.

  • Glenn Walthall

    Glenn Walthall

    Director

    Learn more about Glenn Walthall

    Glenn serves as Gaston Capital’s Managing Partner. His career spans thirty years as a venture capitalist, investment banker, bank executive and consultant. Glenn is currently the Chairman of Bold Therapeutics, and Intezyne Technologies, and a board member of Enviro-Master International, SMRxT, and Mobility Designed. He resides in Charlotte (NC), and has a BS and MBA from Virginia Tech.

Scientific Advisory Board

  • Greg Cole

    Greg Cole, PhD

    UCLA Medical Center

    Learn more about Greg Cole, PhD

    Professor of Medicine and Neurology at UCLA Medical Center, Dr. Cole is also Associate Director of the UCLA Alzheimer's Center, and Associate Director for Research at the Geriatric Research, Education and Clinical Center for the Greater Los Angeles Veterans Administration System.

  • Doug Galasko

    Doug Galasko, MD

    UC San Diego Health

    Learn more about Doug Galasko, MD

    Dr. Galasko is a Neurologist (specialist with Brain Health and Memory Disorders program) and Professor of Neurosciences at UCSD Health, as well as Associate Director of the UC San Diego Shiley-Marcos Alzheimer's Disease Research Center.

  • Lynne Hughes

    Lynne Hughes, PhD

    IQVIA (ret.)

    Learn more about Lynne Hughes, PhD

    Former VP and Global Head, Medical Strategy, Neurology at IQVIA, Dr. Hughes is currently a member of the NIA-NIH task force for recruitment into Alzheimer’s trials and of the G7 & G20 World Dementia Councils. She is also co-chair of the DAVOS (DAC) taskforce for expediting clinical Alzheimer’s trials.

  • Miia Kivipelto

    Miia Kivipelto, MD, PhD

    Karolinska Institute

    Learn more about Miia Kivipelto, MD, PhD

    Dr. Kivipelto is Director of Research, Development, Education and Innovation at Karolinska Institute, in addition to a Karolinska University Hospital Professor. She is also a leader of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGERS) trial, which studies lifestyle intervention for Alzheimer’s disease.

  • Mark Selna

    Mark Selna, MD

    CEO, Health Plan

    Learn more about Mark Selna, MD

    With over 30 years' experience in health system and health plan leadership, as well as in medical practice, Dr. Selna most recently served as President and CEO of Quartz. He is also co-founder of an AI company using data and algorithms to help health systems improve financial, operational, and clinical outcomes.

  • Roy Twyman

    Roy Twyman, MD

    Janssen (ret.)

    Learn more about Roy Twyman, MD

    A longtime leader in the Neuroscience Therapeutic area, Dr. Twyman was the Senior Vice President at Janssen Pharmaceutical Research & Development LLC, where he oversaw Alzheimer’s Disease Therapeutics.

  • Eugeen Vanmechelen

    Eugeen Vanmechelen, PhD

    Fujirebio / ADx NeuroSciences NV

    Learn more about Eugeen Vanmechelen, PhD

    With over 30 years’ research experiences, Dr. Vanmechelen is founder and CSO at ADX, which researches and quantifies biomarkers for neurodegenerative disease. He is also involved in multiple international projects, including the EU Miriade Project, which is working to discover and clinically validate biomarkers for dementia.

  • Larry Ward

    Larry Ward, PhD

    Medicines Development for Global Health

    Learn more about Larry Ward, PhD

    With over 20 years’ biotech experience at companies including AMRAD, Virax, CRC for Mental Health, and Medicines Development for Global Health, Dr. Ward is currently COO at Medicines Development for Global Health, as well as Head of Business Development at CRC for Mental Health and Australian Imaging, Biomarker and Lifestyle Study of Ageing.

BrainHealth Team

  • Steven Verdooner

    Steven Verdooner

    CEO, Director & Founder

    Learn more about Steven Verdooner

    Results-driven executive with over 30 years of experience in medical device markets, with a proven track record of launching successful startups. Steve spends his time thinking about how to solve big medical problems.

  • Richard Travis Wilkes

    Richard Travis Wilkes, MD

    Chief Medical Officer

    Learn more about Richard Travis Wilkes, MD

    Dr. Wilkes is a board-certified physician with an extensive background in biopharma and laboratory innovation. He serves on several medical advisory boards while also maintaining a clinical practice focused on applying cutting-edge technology to personalized patient care.

  • Leyla Anderson

    Leyla Anderson, MD, PhD, D(ABMLI)*

    VP Biomarker Development

    Learn more about Leyla Anderson, MD, PhD, D(ABMLI)*

    Has 20 years of experience in medical research, infectious diseases and immunology, biomarker development, diagnostics, and laboratory medicine. *Diplomate, American Board of Medical Laboratory Immunology (CLIA-approved)

  • Mieko Chambers

    Mieko Chambers, MS

    VP Operations

    Learn more about Mieko Chambers, MS

    Has over 10 years of experience in academic and medical device settings. Experience in a variety of research compliance areas, including clinical trials and human subject research, as well as leading quality and regulatory teams. Mieko has directed several clinical trials and collaborated with many mainstream large pharmaceutical companies.

  • Traci Chu

    Traci Chu

    VP CRM

    Learn more about Traci Chu

    Traci is an ecommerce, CRM, and performance marketer with over 30 years' experience at lifestyle, marketing analytics, and health/med-tech companies. Though she spent her early years at behemoths Mattel and Williams-Sonoma, she loves launching new products that impact lives.

  • Annamarie Robinson

    Annamarie Robinson

    Sr. Director of Finance

    Learn more about Annamarie Robinson

    With over 32 years of accounting experience in the medical, retail, and manufacturing industries, Annamarie oversees NeuroVision Imaging’s financial operations and HR functions, including policies, compliance, payroll, benefits, and employee support. Her expertise supports sound financial management, operational accountability, and employee well-being across the company.

  • Gary Root

    Gary Root

    Director of Engineering

    Learn more about Gary Root

    Has over 10 years of software development experience in the medical imaging and device industry at previous companies including Philips Healthcare. Passionate about bridging the gap between innovative ideas and product implementation by applying the principles of software and data science to solve problems.

  • Hamad Rehman

    Hamad Rehman

    Software Engineer

    Learn more about Hamad Rehman

    Hamad is a professional software developer with 10 years of experience specializing in Python and the MEAN Stack. He focuses on building fast, scalable, and secure web applications, with expertise spanning both backend development and full stack architecture. Hamad also brings strong experience in DevOps, supporting efficient deployment and operations for modern web platforms.

  • Brian Knauss

    Brian Knauss

    Product Manager

    Learn more about Brian Knauss

    Two decades of experience bringing products to life as an Engineer and Product Manager at high tech companies. Has found his professional home taking startups 0-to-1 as a founder and product leader.

  • Josef Tamory

    Josef Tamory, COA, OSC

    Sr Clinical Applications Specialist

    Learn more about Josef Tamory, COA, OSC

    Josef has more than 20 years of experience in Ophthalmology, including work with private practices, hospitals, and academic and research institutions. He has served as an instructor and speaker at prestigious Annual Review Programs for the Georgetown University Review Courses, as well as JCAHPO/ATPO AAO Annual meetings since 2008.

  • Dawn Lenakakis

    Dawn Lenakakis

    Clinical Staff Manager

    Learn more about Dawn Lenakakis

    Dawn brings over 20 years of experience in the medical field, with a strong focus on clinical research in cognitive neurology. She’s passionate about helping patients through every step of their care, acting as a trusted connection between them and their doctors. She combines strong clinical knowledge with genuine commitment to compassionate, well-coordinated care.

 — PARTNERSHIPS & AFFILIATIONS — 

 

Built on trust with the institutions defining cognitive care. 

NeuroVision works alongside leading academic medical centers, research institutions, and industry partners to advance the science and delivery of early cognitive disease detection.